A medicine first used centuries ago may soon make a comeback in modern heart failure treatment after researchers reported encouraging new results showing that low-dose digoxin may help patients avoid hospitalization and live longer.
Scientists from University Medical Center Groningen carried out three studies examining the effects of low-dose digoxin in people with heart failure. Their findings were published in journals including Nature Medicine and JAMA and presented at the ESC Heart Failure Congress in Barcelona.
Heart failure is a major health problem worldwide. The condition develops when the heart can no longer pump blood effectively enough to meet the body’s needs. This can happen because the heart becomes weak, stiff, or damaged over time.
As blood flow worsens, patients may develop fatigue, breathing problems, swelling, and difficulty performing everyday activities. Many patients also require repeated hospital treatment when symptoms suddenly worsen.
Despite major advances in medicine, heart failure remains one of the leading causes of hospitalization in older adults.
Doctors currently rely on four major groups of medications to treat the condition. These treatments are sometimes called the “Fantastic Four” because together they improve survival and reduce complications for many patients.
Researchers have long questioned whether digoxin could serve as a useful fifth medicine added to this standard combination.
Digoxin has a long and complicated history in heart medicine. It was originally developed from compounds found in the foxglove plant and has been used for hundreds of years.
In earlier decades, doctors often prescribed relatively high doses to strengthen the heart’s pumping action. However, higher doses sometimes caused dangerous side effects, especially abnormal heart rhythms and toxicity.
As newer medications became available over the past 25 to 30 years, digoxin gradually became less common.
More recently, scientists discovered that lower doses may provide benefits without causing many of the earlier safety concerns.
Instead of strongly stimulating the heart muscle, low-dose digoxin mainly appears to reduce harmful stress responses that occur in heart failure. Researchers say it lowers levels of stress hormones such as adrenaline, which may help reduce strain on the heart.
To investigate the effects more carefully, researchers studied about 1,000 heart failure patients treated at 43 centers across the Netherlands.
Half of the patients received low-dose digoxin in addition to their standard heart failure medications, while the other half received a placebo. Patients continued treatment for an average of three years.
The researchers observed a 19% reduction in the combined risk of worsening heart failure and cardiovascular death among patients receiving digoxin. Although the first study alone did not show statistically significant results, scientists then combined the data with two earlier studies.
This larger meta-analysis provided stronger evidence that low-dose digoxin offered real benefits for heart failure patients.
One of the clearest benefits was a reduction of approximately 25% in heart failure hospital admissions.
Researchers also reported that the low-dose treatment appeared safe and easy for patients to tolerate.
Another important part of the research involved patients who stopped taking digoxin after previously receiving it.
Scientists followed about 600 participants who had either received digoxin or placebo. Patients who stopped digoxin experienced noticeably more problems during the first six weeks after discontinuing the medication.
Among 288 patients who stopped taking digoxin, 14 were hospitalized or died during this short follow-up period.
Although researchers say this does not fully prove cause and effect, they described the findings as striking and unexpected.
The results are attracting attention because digoxin is far cheaper than many newer heart failure medications. Researchers estimated the cost at less than ten cents per day, while some modern heart failure drugs cost several euros daily.
Because heart failure is so common and hospital admissions are expensive, even a relatively small reduction in hospitalizations could have major benefits for both patients and healthcare systems.
Researchers believe the findings may eventually influence future treatment guidelines and encourage more doctors to consider low-dose digoxin for selected patients.
At present, only about 15% of heart failure patients are prescribed the medicine.
Still, experts caution that the results should be interpreted carefully. Digoxin can still be dangerous if used incorrectly or at doses that are too high. Proper monitoring and dosing remain important.
The study also highlights how older medications may sometimes regain importance as scientists learn better ways to use them.
Modern medicine often focuses on developing new and expensive treatments, but the research suggests that older affordable drugs may still provide valuable benefits when combined with newer therapies.
Researchers now hope future studies will continue examining which heart failure patients benefit most from low-dose digoxin and how the medicine can best be combined with modern heart failure treatments.
The findings offer hope that a very old and inexpensive medication may still help improve quality of life and reduce hospital stays for many people living with heart failure.
If you care about heart health, please read studies about top 10 foods for a healthy heart, and how to eat right for heart rhythm disorders.
For more health information, please see recent studies about how to eat your way to cleaner arteries, and salt and heart health: does less really mean more?
Source: University Medical Center Groningen.
